Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo

Zhang, Ping, Tey, Siok-Keen, Koyama, Motoko, Kuns, Rachel D., Olver, Stuart D., Lineburg, Katie E., Lor, Mary, Teal, Bianca E., Raffelt, Neil C., Raju, Jyothy, Leveque, Lucie, Markey, Kate A., Varelias, Antiopi, Clouston, Andrew D., Lane, Steven W., Macdonald, Kelli P. A. and Hill, Geoffrey R. (2013) Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. Journal of Immunology, 191 10: 5291-5303. doi:10.4049/jimmunol.1301181

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Zhang, Ping
Tey, Siok-Keen
Koyama, Motoko
Kuns, Rachel D.
Olver, Stuart D.
Lineburg, Katie E.
Lor, Mary
Teal, Bianca E.
Raffelt, Neil C.
Raju, Jyothy
Leveque, Lucie
Markey, Kate A.
Varelias, Antiopi
Clouston, Andrew D.
Lane, Steven W.
Macdonald, Kelli P. A.
Hill, Geoffrey R.
Title Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo
Journal name Journal of Immunology   Check publisher's open access policy
ISSN 0022-1767
Publication date 2013-11-15
Sub-type Article (original research)
DOI 10.4049/jimmunol.1301181
Open Access Status Not Open Access
Volume 191
Issue 10
Start page 5291
End page 5303
Total pages 13
Place of publication Bethesda MD, United States
Publisher American Association of Immunologists
Collection year 2014
Language eng
Subject 2403 Immunology
Abstract Natural regulatory T cells (nTregs) play an important role in tolerance; however, the small numbers of cells obtainable potentially limit the feasibility of clinical adoptive transfer. Therefore, we studied the feasibility and efficacy of using murine-induced regulatory T cells (iTregs) for the induction of tolerance after bone marrow transplantation. iTregs could be induced in large numbers from conventional donor CD4 and CD8 T cells within 1 wk and were highly suppressive. During graft-versus-host disease (GVHD), CD4 and CD8 iTregs suppressed the proliferation of effector T cells and the production of proinflammatory cytokines. However, unlike nTregs, both iTreg populations lost Foxp3 expression within 3 wk in vivo, reverted to effector T cells, and exacerbated GVHD. The loss of Foxp3 in iTregs followed homeostatic and/or alloantigen-driven proliferation and was unrelated to GVHD. However, the concurrent administration of rapamycin, with or without IL-2/anti-IL-2 Ab complexes, to the transplant recipients significantly improved Foxp3 stability in CD4 iTregs (and, to a lesser extent, CD8 iTregs), such that they remained detectable 12 wk after transfer. Strikingly, CD4, but not CD8, iTregs could then suppress Teff proliferation and proinflammatory cytokine production and prevent GVHD in an equivalent fashion to nTregs. However, at high numbers and when used as GVHD prophylaxis, Tregs potently suppress graft-versus-leukemia effects and so may be most appropriate as a therapeutic modality to treat GVHD. These data demonstrate that CD4 iTregs can be produced rapidly in large, clinically relevant numbers and, when transferred in the presence of systemic rapamycin and IL-2, induce tolerance in transplant recipients. Copyright
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 25 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 23 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 30 Jan 2014, 15:06:28 EST by Matthew Lamb on behalf of School of Medicine